Posttranslational modifications of recombinant myotube-synthesized human factor IX.
about
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia BNew developments in the management of moderate-to-severe hemophilia BAdeno-associated virus: from defective virus to effective vectorGene therapy for hemophiliaTranslational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogsThe potential of adeno-associated viral vectors for gene delivery to muscle tissue.Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.AAV-mediated gene transfer for hemophilia.Non-viral gene delivery in skeletal muscle: a protein factory.Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.Gene therapy in orthopaedic surgery: the current status.Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal modelSystemic protein delivery by muscle-gene transfer is limited by a local immune response.A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin.Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.Post-translational modifications in the context of therapeutic proteins.Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.Activation mechanisms of coagulation factor IX.Therapeutic plasma proteins--application of proteomics in process optimization, validation, and analysis of the final product.Role of tyrosine-sulfated proteins in retinal structure and functionObstacles and future of gene therapy for hemophilia.In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.Stable and high-level production of recombinant Factor IX in human hepatic cell line.An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle.Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle.Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus.Muscle Gene Therapy for Hemophilia.Capsid-modified adenoviral vectors for improved muscle-directed gene therapyDirect comparison of four adeno-associated virus serotypes in mediating the production of antiangiogenic proteins in mouse muscle.Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays.Engineering liver tissues under the kidney capsule site provides therapeutic effects to hemophilia B mice.Soluble TNF-α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer.Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX.Distinguishing Sulfotyrosine Containing Peptides from their Phosphotyrosine Counterparts Using Mass Spectrometry.
P2860
Q21245486-2CF311EE-F676-4676-B57E-5156E464FA28Q26751323-D6856F69-F543-4CA5-AA77-AE54CB67F531Q27498163-37F4ACC0-272A-4AE1-88E3-A96E9547736FQ28081911-57259C56-5107-4C00-BD07-763F98BDD592Q30891500-5A6BF97A-2636-4A69-966D-8E765DEB224DQ33902499-67B16611-55A4-4E32-9426-4072090C4D7AQ33931862-DB143772-0BDD-423F-AA37-991E1A3E521CQ34078730-DDC7B224-B9B3-413D-8FE6-DD96128F0769Q34497332-8C48C719-A339-4B28-8FC8-A41EF71BD119Q35061706-807FC3D5-78C0-4376-9442-5463D631FCFFQ35157358-025EAE1E-04E2-4A37-BD50-00A3BD684C29Q35630146-A16F6FA7-6804-43DE-8137-22199975FB01Q35847459-50324307-8F19-4B70-936A-E7497610D78CQ35847626-C4739C38-3EEF-4FD1-A057-02147D3BD016Q36024071-22C6DDE4-BFD8-4AAA-AF3F-574E8A47F4AFQ36230845-0B6496BC-2C23-4DE0-8640-20B38DD0FB24Q36438711-B6833311-61A9-4168-9D20-4E240EDFF9C5Q36620451-ABAE8D17-D7CC-4015-8905-462113505B42Q36873312-1C9FD3E2-6C36-4D91-9429-7E2707110F91Q37441223-688DFE22-FCAF-4AA2-95F7-AF9ECE63D2E2Q37872258-AFCCAF80-496C-4173-9A13-5F205A8370C2Q38394797-2CCDDA85-BD9E-4A08-B439-B3A0227A2B7EQ38529941-291AE015-4FF0-40EC-AF33-D0BCA50AA25CQ38873929-CFABE3C9-C0C8-4F6D-934B-8623CA63FA96Q39490991-20F77242-4368-4DD0-9E5B-6614A9B3AEC4Q39613077-71F1165A-2DC2-4CB8-A562-DBE45F76E067Q39639059-0FB817CF-EB94-4C47-A240-0DCE9542B97AQ39685864-2040E319-AE1C-4546-A785-C1A4ACB1CC29Q40055959-A2CFFA6B-19B8-45E8-AC69-E79F59165563Q42424335-CAB92889-F380-4C8D-B334-44E549E795A8Q43427810-6E9856D6-2CB6-4A32-9AF7-894724F7C156Q45857947-01BA9DCF-3868-40DD-B207-CBEE5D24A39BQ45861526-9941BADE-AF06-4D37-BB20-155C8744FFDDQ45861904-ACD56530-19D7-4911-96E4-92A26EFE1B2AQ46935173-34F98A49-A5B1-4566-B81E-D8519909A74DQ50127788-9F475EF3-9860-410A-A29A-BE78680CBB4B
P2860
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
@en
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
@nl
type
label
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
@en
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
@nl
prefLabel
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
@en
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
@nl
P2093
P356
P1433
P1476
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
@en
P2093
Hagstrom JN
Heiman-Patterson T
P304
P356
10.1182/BLOOD.V97.1.130
P407
P577
2001-01-01T00:00:00Z